Alicia Okines - Concepedia

Author

Alicia Okines

Royal Marsden NHS Foundation Trust ORCID

Also Known As

A Okines, A. F. C. Okines, A. F. Okines, A. Okines, A.F. Okines, A.F.C. Okines, Alicia FC Okines, Alicia F C Okines, Alicia F Okines, Alicia F. C. Okines

265

Publications

12.6K

Citations

H-Index

Concepts

All Affiliations

Royal Marsden NHS Foundation Trust Royal Marsden Hospital Institute of Cancer Research University College London Weston Park Cancer Centre

About

Alicia Okines is an author at Royal Marsden NHS Foundation Trust specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	29	5.7K
2	Health Sciences	3	3	118
3	Public Health	3	3	1.8K
4	Emergency Medicine	2	2	94
5	Epidemiology	2	2	1.7K

Alicia Okines

Publications

11.5K

Citations

H-Index

Page 1

	Year	Citations
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Alicia Okines, Marcel Verheij, William Allum, Annals of Oncology EsophagusGastrointestinal OncologyMedicineGastroenterologySurgery	2010	1.3K
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Rashmi K. Murthy, Sherene Loi, Alicia Okines, New England Journal of Medicine	2019	1.3K
COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Lennard Y. W. Lee, Jean‐Baptiste Cazier, Vasileios Angelis, The Lancet Covid-19 MortalityEpidemiologyCancer EpidemiologyMedicineCancer Management	2020	1.1K
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Ian Chau, David Cunningham, David González, The Lancet Oncology OncologyOpen-label Phase 3Cancer ManagementPathologyCancer Treatment	2013	723
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study Lennard Y. W. Lee, Jean‐Baptiste Cazier, Thomas Starkey, The Lancet Oncology Primary Tumour SubtypeEpidemiologyCancer EpidemiologyCovid-19 PrevalenceMedicine	2020	599
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi, The Lancet Long CovidAntimicrobial StewardshipAntibioticsClinical InfectionPlatform Trial	2021	555
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial Nancy U. Lin, Virginia F. Borges, Carey K. Anders, Journal of Clinical Oncology	2020	521
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet	2021	516
Mismatch Repair Deficiency, Microsatellite Instability, and Survival Elizabeth Smyth, Andrew Wotherspoon, Clare Peckitt, JAMA Oncology	2017	509
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Obbina Abani, Ali Abbas, Fatima Abbas, The Lancet Covid-19 PandemicAntiviral TherapyClinical TrialsPlatform TrialMedicine	2022	382

Page 1